Physician profile
Jason E Stanton
NPI 1154853315
$7,294.04
in general payments reported to CMS, 2019-2025
54 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $420 · 2021: $885 · 2022: $1,735 · 2023: $1,602 · 2024: $1,462 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,253.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,128.73 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $651.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $548.90 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $542.83 | 2020-2025 | Ubrelvy, Synthroid, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.40 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $344.99 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $321.82 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $278.89 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $273.97 | 2022-2024 | |
| Stryker Corporation | $234.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $226.02 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.30 | 2021-2025 | Jardiance |
| Amgen INC. | $182.84 | 2020-2025 | Prolia, Evenity, Repatha |
| Esperion Therapeutics, INC. | $178.11 | 2020-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $174.52 | 2022 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $121.78 | 2020-2022 | |
| Lucid Diagnostics INC. | $113.12 | 2022-2023 | |
| Dexcom, INC. | $105.32 | 2021-2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $93.35 | 2023-2025 | Accrufer |
| Phathom Pharmaceuticals, INC. | $71.77 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $68.28 | 2021 | |
| Dynavax Technologies Corporation | $65.19 | 2021-2025 | Heplisav-B |
| Nevro Corp. | $64.33 | 2021-2023 | Senza |
| Hologic Sales and Service, LLC | $64.14 | 2022-2024 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Exact Sciences Corporation | $63.76 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $63.11 | 2023 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $58.53 | 2022-2023 | Prehevbrio |
| Horizon Therapeutics Plc | $53.02 | 2021-2023 | Krystexxa |
| Eisai INC. | $45.04 | 2020-2022 | |
| Phadia US INC. | $41.42 | 2023-2024 | Immunocap |
| Astellas Pharma US INC | $41.38 | 2021-2025 | Veozah |
| Acerus Pharmaceuticals Corporation | $41.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.12 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $33.65 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.84 | 2022-2023 | Eliquis |
| Sumitomo Pharma America, INC. | $27.86 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $27.72 | 2022-2023 | Contrave |
| Kowa Pharmaceuticals America, INC. | $25.61 | 2022-2023 | Livalo, Seglentis |
| Alk-Abello, INC | $23.03 | 2022 | |
| Inari Medical, INC. | $22.64 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Coloplast Corp | $22.33 | 2024 | |
| Merck Sharp & Dohme LLC | $20.04 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Corcept Therapeutics | $19.59 | 2025 | Korlym |
| Ibsa Pharma INC. | $17.41 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.74 | 2023 | Evkeeza |
| Jazz Pharmaceuticals INC. | $16.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.72 | 2022 | |
| Philips North America LLC | $14.89 | 2022 | |
| Lundbeck LLC | $14.55 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $13.87 | 2023 | Lyvispah |
| Nabriva Therapeutics, Plc | $13.43 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.06 | 2020 | |
| Clarus Therapeutics INC. | $10.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.